본문 바로가기

Change in Severity and Clinical Manifestation of MIS-C Over SARS-CoV-2 Variant Outbreaks in Korea

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1KCI Q1
피인용
Web of Science 15Scopus 15KCI 1
FWCI (Scopus)
1.93
JCR IF
JCR 2022 4.5
ISSN
1011-8934

저자

  1. Choe, Young June제1저자고려대학교, Department of Pediatrics, KO
  2. Choi, Eun Hwa교신저자서울대학교, Department of Pediatrics, KO
  3. Choi, Jong Woon분당제생병원, Bundang Jesaeng General Hospital, KO
  4. Eun, Byung Wook을지대학교, Department of Pediatrics, KO
  5. Eun, Lucy Youngmin연세대학교, Department of Laboratory Medicine, KO
  6. Kim, Yae Jean성균관대학교, Department of Pediatrics, KO
  7. Kim, Yeo Hyang경북대학교, Department of Pediatrics, KO
  8. 김영아부산대학교, 의과대학, 의학과, KO
  9. Kim, Yun Kyung고려대학교, Department of Pediatrics, KO
  10. Kwak, Ji Hee경북삼성병원, Department of Pediatrics, KO
  11. Lee, Hyukmin연세대학교, Department of Laboratory Medicine, KO
  12. Park, June Dong서울대학교, Department of Pediatrics, KO
  13. Jung, Yeon Haw연세대학교, Department of Laboratory Medicine, KO
  14. Gwack, Jin질병관리청, Korea Disease Control and Prevention Agency, KO
  15. Lee, Sangwon질병관리청, Korea Disease Control and Prevention Agency, KO

초록

BACKGROUND: There is difference in the incidence of multi-system inflammatory syndrome in children (MIS-C) in patients with different variants of severe acute respiratory syndrome coronavirus 2, however, little is known about the epidemiology in Asian countries. We investigated and compared the epidemiology of the MIS-C during omicron-dominant period with that of previous periods in South Korea. METHODS: We obtained clinical, epidemiological and laboratory data on MIS-C cases from national MIS-C surveillance in South Korea. We defined pre-delta period as January 2020-May 2021; delta period as June 2021-December 2021; and omicron period as January 2022-April 2022. We describe the clinical characteristics and outcomes of MIS-C patients by period. RESULTS: A total of 91 cases were assessed to be MIS-C cases. Number of MIS-C cases have increased from six cases during pre-delta period to 66 cases during omicron period, while the incidence rate (the number of MIS-C cases per 100,000 cases of reported coronavirus disease 2019) has decreased from 38.5 cases per 100,000 (95% confidence interval [CI], 14.1-83.9) during pre-delta period to 1.6 cases per 100,000 (95% CI, 1.2-2.0) during omicron periods. During pre-delta period, 66.7% and 100% had hypotension and gastrointestinal involvement, respectively; while during omicron period, 12.1% and 6.1% had such clinical manifestations. Fifty percent of pre-delta MIS-C patients were taken intensive care unit (ICU) cares, while 10.6% of patients during omicron periods were in ICUs. CONCLUSION: Omicron period were associated with less severe clinical manifestation compared to pre-delta and delta periods. Although incidence rate of MIS-C was lower for the omicron period than pre-delta and delta periods, number of patients reported with MIS-C may pose a substantial clinical burden.

키워드

COVID-19MIS-CSARS-CoV-2MULTISYSTEM INFLAMMATORY SYNDROMEOMICRON VARIANTSOUTH-KOREADISEASECHILDRENSURVEILLANCEVACCINE

식별자

Scopus EID
2-s2.0-85166105269
WoS UID
001043974700004
KCI
ART002983510